• Home
  • NEW DAY MEDICINE
  • 11 (49) 2022
  • 4 -11 (49) 2022 — Daminova L.T., Adilova D.Sh. — RISK FACTORS FOR THE DEVELOPMENT OF POST-COVID FIBROSIS OF THE HEPATIC PARENCHYMA

4 -11 (49) 2022 — Daminova L.T., Adilova D.Sh. — RISK FACTORS FOR THE DEVELOPMENT OF POST-COVID FIBROSIS OF THE HEPATIC PARENCHYMA

RISK FACTORS FOR THE DEVELOPMENT OF POST-COVID FIBROSIS OF THE HEPATIC PARENCHYMA

Daminova L.T., Tashkent State Dental Institute. Tashkent, Uzbekistan.

Adilova D.Sh. Tashkent Pediatric Medical Institute. Tashkent, Uzbekistan.

Resume

The purpose of the study: to determine the risk of development and progression of structural changes in the liver parenchyma in patients with COVID-19.

Materials and research methods. 243 patients who underwent COVID-19 were under observation. All patients were divided into 4 therapeutic groups depending on the use of hepatoprotectors. The control examination was carried out in a month. All patients were determined enzymes in the blood serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl aminotransferase (GGT), lactate dehydrogenase (LDH), alkaline phosphatase (AP), total and direct bilirubin, albumin, abdominal ultrasound and liver elastometry. To identify patients at risk of developing and progressing fibrosis of the liver parenchyma after SARS-CoV2 infection, all patients were divided into 2 groups: patients with a tendency to develop fibrosis of the hepatic parenchyma – F+ (28 people) and patients with a tendency to normal liver stiffness – F- ( 215 people) and conducted a retrospective analysis of factors predisposing to the development of fibrosis.

Conclusion. Among patients who have undergone COVID-19 and have biochemical signs of a violation of the functional state of the liver, in 28 patients (11.52%) there is a tendency to form fibrosis of the hepatic parenchyma. The applied hepatoprotectors did not demonstrate a preventive effect in terms of the risk of difference and progression of fibrosis in these patients. Fibrosis risk predictors are a history of autoimmune hepatitis (diagnostic value 87.65%, p<0.01), LDH concentration in peripheral blood serum more than (472.33 U/l, diagnostic value 95.88%, p<0.001), F2-3 in the early post-COVID period (diagnostic value 88.07%, p<0.001).

Keywords: Covid-19, hepatoprotectors, liver fibrosis

First page

17

Last page

23

For citation:Daminova L.T., Adilova D.Sh. – RISK FACTORS FOR THE DEVELOPMENT OF POST-COVID FIBROSIS OF THE HEPATIC PARENCHYMA //New Day in Medicine 11(49)2022 17-23 https://clck.ru/32cwes

LIST OF REFERENCES:

  1. Mao R., Qiu Y., He J.S., Tan J.Y., Li X.H., Liang J., Shen J., Zhu L.R., Chen Y., Iacucci M., Ng S.C., Ghosh S., Chen M.H. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. // Lancet Gastroenterol Hepatol. 2020; 5:667–678.
  2. El Ouali S., Romero-Marrero C., Regueiro M. Hepatic manifestations of COVID-19. // Cleve Clin J Med. 2020
  3. Feng G., Zheng K.I., Yan Q.Q., Rios R.S., Targher G., Byrne C.D., Poucke S.V., Liu W.Y., Zheng M.H. COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. // J Clin Transl Hepatol. 2020; 8:18–24.
  4. Cao J., Cai X., Chen M. Liver Injury in COVID-19: Caution and Management. // Liver Cancer. 2020;9:625–626.
  5. Li F., Li W., Farzan M., Harrison S.C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. // Science. 2005; 309:1864–1868.
  6. Mahamid M., Nseir W., Khoury T., Mahamid B., Nubania A., Sub-Laban K., Schifter J., Mari A., Sbeit W., Goldin E. Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study. // Eur J Gastroenterol Hepatol. 2020
  7. Lei F., Liu Y.M., Zhou F., Qin J.J., Zhang P., Zhu L., Zhang X.J., Cai J., Lin L., Ouyang S., Wang X., Yang C., Cheng X., Liu W., Li H., Xie J., Wu B., Luo H., Xiao F., Chen J., Tao L., Cheng G., She Z.G., Zhou J., Wang H., Lin J., Luo P., Fu S., Ye P., Xiao B., Mao W., Liu L., Yan Y., Chen G., Huang X., Zhang B.H., Yuan Y. Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. // Hepatology. 2020; 72:389–398.
  8. Phipps M.M., Barraza L.H., LaSota E.D., Sobieszczyk M.E., Pereira M.R., Zheng E.X., Fox A.N., Zucker J., Verna E.C. Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort. // Hepatology. 2020;72:807–817
  9. Richardson S., Hirsch J.S., Narasimhan M., Crawford J.M., McGinn T., Davidson K.W. The Northwell COVID-19 Research Consortium.
  10. Barnaby D.P., Becker L.B., Chelico J.D., Cohen S.L., Cookingham J., Coppa K., Diefenbach M.A., Dominello A.J., Duer-Hefele J., Falzon L., Gitlin J., Hajizadeh N., Harvin T.G., Hirschwerk D.A., Kim E.J., Kozel Z.M., Marrast L.M., Mogavero J.N., Osorio G.A., Qiu M., Zanos T.P. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. // JAMA. 2020; 323:2052–2059.
  11. Vespa E., Pugliese N., Piovani D., Capogreco A., Danese S., Aghemo A Humanitas Covid-19 Task Force. Liver tests abnormalities in COVID-19: trick or treat? // J Hepatol. 2020; 73:1275–1276.

file

download